Krishnaswamy Yeleswaram

RAPP

CHIEF DEVELOPMENT OFFICER · RAPPORT THERAPEUTICS, INC. · CIK 0002022156

FILING MIX · LIFETIME33%/67%

BUYS

SELLS

TOTAL VALUE

$1.93M

COMPANIES

ACTIVE SINCE

Jun 2024

HOLDINGS NOW

246,022

AVG SELL PX

$35.79

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

7 backtested trades · 8 horizons · 20 pendingHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Krishnaswamy Yeleswaram, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	7	+28.57%	+5.08%	+2.02%	+3.06%	+3.89%	—
14d	7	+42.86%	+0.58%	+3.23%	-2.66%	-2.07%	—
30d	7	+28.57%	+7.27%	+6.82%	+0.46%	+1.71%	—
60d	7	+42.86%	+3.65%	+6.53%	-7.37%	-6.36%	—
90d	7	+0.00%	+16.47%	+7.80%	+8.67%	+7.76%	—
180d	7(6 pending)	+0.00%	+27.95%	+6.90%	+21.05%	+21.05%	—
1y	7(7 pending)	—	—	—	—	—	—
2y	7(7 pending)	—	—	—	—	—	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

RAPP · 246,022 shares · as of Aug 19, 2026

Trading cadence · quarterly flow

BUY ● SELL ●

2024

2025

2026

FLOW · 4 buys / 8 sellsCOVERAGE · 10 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	404	$49.90	$20.2K	246,022	Aug 19, 2026	Aug 20, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	20,225	$39.99	$808.8K	246,426	Apr 17, 2026	Apr 21, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	10,200	$35.08	$357.8K	266,651	Apr 14, 2026	Apr 14, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	9,165	$34.97	$320.5K	276,851	Apr 13, 2026	Apr 14, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	500	$34.98	$17.5K	286,016	Apr 10, 2026	Apr 14, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	360	$34.90	$12.6K	286,516	Apr 8, 2026	Apr 9, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE10b5-1 10b5-1 plan	10,115	$29.99	$303.4K	286,876	Mar 25, 2026	Mar 26, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	120,000	—	—	120,000	Feb 2, 2026	Feb 4, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	9,000	—	—	299,831	Dec 31, 2025	Jan 5, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	SALE Chief Development Officer	2,840	$30.05	$85.3K	296,991	Dec 31, 2025	Jan 5, 2026 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	110,000	—	—	110,000	Feb 3, 2025	Feb 4, 2025 ↗	View →
RAPP RAPPORT THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	84,904	—	—	84,904	Jun 6, 2024	Jun 10, 2024 ↗	View →

Other insiders · RAPP

Loading peer insiders…

About this filer

CIK 0002022156

ROLE

Chief Development Officer

PRIMARY

RAPP

COMPANIES

ACTIVE SINCE

Jun 2024

MARKETPEEL · /INSIDER/0002022156DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Krishnaswamy Yeleswaram

The morning brief, before the bell.